Predictors of sustained clinical response in patients with Beh double dagger et's disease-related uveitis treated with infliximab and adalimumab

To identify clinical variables capable of predicting long-term treatment duration of TNF-alpha inhibition in patients with Behcet's disease (BD)-related uveitis. Demographic, clinical, and therapeutic data were retrospectively collected from BD patients treated with the tumor necrosis factor (TNF)-alpha blockers infliximab and adalimumab. Patients still continuing TNF-alpha inhibitors at 48-month follow-up visits were classified as long-term responders and were statistically compared to patients discontinuing treatment before the 48-month visit. Forty-five patients (75 eyes) were enrolled. Thirty-two patients continued anti-TNF-alpha treatment for more than 48 months; 13 patients discontinued the treatment after a mean time of 12.3 +/- 10.44 months due to lack (61.5%) or loss (38.5%) of efficacy. Baseline value of BD current activity form was the only variable discriminating long- and short-term responsive patients (p = 0.048, OR = 0.656, C.I. 95% 0.433-0.996). Disease activity levels at the start of treatment predict duration of response to monoclonal TNF antagonists in ocular BD.